S&P 500   4,594.97 (+0.62%)
DOW   35,861.34 (+0.34%)
QQQ   382.22 (+1.14%)
AAPL   149.34 (+0.47%)
MSFT   309.91 (+0.58%)
FB   320.87 (-2.38%)
GOOGL   2,769.04 (+0.73%)
TSLA   1,086.92 (+6.06%)
AMZN   3,407.87 (+2.64%)
NVDA   250.80 (+8.26%)
BABA   172.55 (-2.05%)
NIO   42.03 (+1.84%)
CGC   13.54 (-0.22%)
GE   107.57 (+2.16%)
AMD   126.14 (+3.09%)
MU   69.31 (+0.80%)
T   25.60 (-0.16%)
F   16.00 (+0.00%)
ACB   7.14 (-0.56%)
DIS   172.91 (+0.52%)
PFE   43.25 (+0.23%)
BA   213.73 (+0.40%)
AMC   36.37 (-1.25%)
S&P 500   4,594.97 (+0.62%)
DOW   35,861.34 (+0.34%)
QQQ   382.22 (+1.14%)
AAPL   149.34 (+0.47%)
MSFT   309.91 (+0.58%)
FB   320.87 (-2.38%)
GOOGL   2,769.04 (+0.73%)
TSLA   1,086.92 (+6.06%)
AMZN   3,407.87 (+2.64%)
NVDA   250.80 (+8.26%)
BABA   172.55 (-2.05%)
NIO   42.03 (+1.84%)
CGC   13.54 (-0.22%)
GE   107.57 (+2.16%)
AMD   126.14 (+3.09%)
MU   69.31 (+0.80%)
T   25.60 (-0.16%)
F   16.00 (+0.00%)
ACB   7.14 (-0.56%)
DIS   172.91 (+0.52%)
PFE   43.25 (+0.23%)
BA   213.73 (+0.40%)
AMC   36.37 (-1.25%)
S&P 500   4,594.97 (+0.62%)
DOW   35,861.34 (+0.34%)
QQQ   382.22 (+1.14%)
AAPL   149.34 (+0.47%)
MSFT   309.91 (+0.58%)
FB   320.87 (-2.38%)
GOOGL   2,769.04 (+0.73%)
TSLA   1,086.92 (+6.06%)
AMZN   3,407.87 (+2.64%)
NVDA   250.80 (+8.26%)
BABA   172.55 (-2.05%)
NIO   42.03 (+1.84%)
CGC   13.54 (-0.22%)
GE   107.57 (+2.16%)
AMD   126.14 (+3.09%)
MU   69.31 (+0.80%)
T   25.60 (-0.16%)
F   16.00 (+0.00%)
ACB   7.14 (-0.56%)
DIS   172.91 (+0.52%)
PFE   43.25 (+0.23%)
BA   213.73 (+0.40%)
AMC   36.37 (-1.25%)
S&P 500   4,594.97 (+0.62%)
DOW   35,861.34 (+0.34%)
QQQ   382.22 (+1.14%)
AAPL   149.34 (+0.47%)
MSFT   309.91 (+0.58%)
FB   320.87 (-2.38%)
GOOGL   2,769.04 (+0.73%)
TSLA   1,086.92 (+6.06%)
AMZN   3,407.87 (+2.64%)
NVDA   250.80 (+8.26%)
BABA   172.55 (-2.05%)
NIO   42.03 (+1.84%)
CGC   13.54 (-0.22%)
GE   107.57 (+2.16%)
AMD   126.14 (+3.09%)
MU   69.31 (+0.80%)
T   25.60 (-0.16%)
F   16.00 (+0.00%)
ACB   7.14 (-0.56%)
DIS   172.91 (+0.52%)
PFE   43.25 (+0.23%)
BA   213.73 (+0.40%)
AMC   36.37 (-1.25%)
NASDAQ:RCKT

Rocket Pharmaceuticals Stock Forecast, Price & News

$29.66
-0.05 (-0.17 %)
(As of 10/26/2021 10:42 AM ET)
Add
Compare
Today's Range
$29.32
$29.81
50-Day Range
$27.42
$36.58
52-Week Range
$26.72
$67.48
Volume508 shs
Average Volume434,516 shs
Market Capitalization$1.91 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.72
30 days | 90 days | 365 days | Advanced Chart
Receive RCKT News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Rocket Pharmaceuticals logo

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in New York, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCKT
Employees
101
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$9.12 per share

Profitability

Net Income
$-139.70 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.91 billion
Next Earnings Date
11/3/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.54 out of 5 stars

Medical Sector

228th out of 1,360 stocks

Pharmaceutical Preparations Industry

100th out of 667 stocks

Analyst Opinion: 4.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions

Is Rocket Pharmaceuticals a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Rocket Pharmaceuticals stock.
View analyst ratings for Rocket Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Rocket Pharmaceuticals?

Wall Street analysts have given Rocket Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rocket Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Rocket Pharmaceuticals' next earnings date?

Rocket Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Rocket Pharmaceuticals
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) released its quarterly earnings data on Monday, August, 9th. The biotechnology company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.11. During the same period last year, the company earned ($0.45) EPS.
View Rocket Pharmaceuticals' earnings history
.

How has Rocket Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Rocket Pharmaceuticals' stock was trading at $15.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RCKT shares have increased by 85.5% and is now trading at $29.66.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RCKT?

11 Wall Street analysts have issued 12-month price objectives for Rocket Pharmaceuticals' shares. Their forecasts range from $43.00 to $100.00. On average, they anticipate Rocket Pharmaceuticals' share price to reach $69.38 in the next twelve months. This suggests a possible upside of 133.9% from the stock's current price.
View analysts' price targets for Rocket Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Rocket Pharmaceuticals' key executives?

Rocket Pharmaceuticals' management team includes the following people:
  • Gaurav Shah, President, Chief Executive Officer & Director
  • Kinnari Patel, Chief Operating Officer & EVP-Development
  • Carlos Garcia-Parada, Chief Financial Officer
  • Jonathan David Schwartz, Chief Medical Officer & SVP-Clinical Development
  • Isabel Carmona, Chief Human Resources Officer & Senior VP

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.05%). Company insiders that own Rocket Pharmaceuticals stock include Gotham Makker, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends for Rocket Pharmaceuticals
.

Which major investors are selling Rocket Pharmaceuticals stock?

RCKT stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have sold Rocket Pharmaceuticals company stock in the last year include Gotham Makker, Kinnari Patel, and Rtw Investments, Lp.
View insider buying and selling activity for Rocket Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $29.66.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals has a market capitalization of $1.91 billion. The biotechnology company earns $-139.70 million in net income (profit) each year or ($2.52) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

Rocket Pharmaceuticals employs 101 workers across the globe.

What is Rocket Pharmaceuticals' official website?

The official website for Rocket Pharmaceuticals is www.rocketpharma.com.

Where are Rocket Pharmaceuticals' headquarters?

Rocket Pharmaceuticals is headquartered at 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at (646) 440-9100 or via email at [email protected].


This page was last updated on 10/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.